Famotidine
Generic Name: famotidine
Brand Names:
Famotidine
Famotidine is a histamine-2 (H2) receptor antagonist available as film-coated tablets for oral administration.
Overview
Famotidine is a histamine-2 (H2) receptor antagonist available as film-coated tablets for oral administration.
Uses
Treatment of active duodenal ulcer, active gastric ulcer, symptomatic nonerosive GERD, and erosive esophagitis due to GERD in adult and pediatric patients 40 kg and greater. Also for pathological hypersecretory conditions and duodenal ulcer recurrence reduction in adults.
Dosage
Active duodenal ulcer: 40 mg once daily or 20 mg twice daily (up to 8 weeks). Active gastric ulcer: 40 mg once daily (up to 8 weeks). GERD: 20 mg twice daily (up to 6 weeks). Erosive esophagitis: 20-40 mg twice daily (up to 12 weeks). Take once daily before bedtime or twice daily in morning and before bedtime.
Side Effects
Most common: headache, dizziness, constipation, and diarrhea. Less common: CNS effects, cardiovascular, GI, hematologic, and hypersensitivity reactions. Postmarketing: arrhythmia, jaundice, agranulocytosis, anaphylaxis, Stevens-Johnson syndrome.
Interactions
Reduces absorption of drugs dependent on gastric pH (dasatinib, delavirdine, cefditoren, fosamprenavir). May increase tizanidine concentrations; avoid concomitant use if possible.
Warnings
CNS adverse reactions in elderly and renally impaired patients; reduce dosage accordingly. Absence of GI symptoms does not exclude gastric malignancy; evaluate prior to initiating therapy. Contraindicated with history of serious hypersensitivity reactions to famotidine or other H2 receptor antagonists.
Pregnancy
Limited human data; animal studies showed no adverse development effects at doses up to 243 times the recommended human dose. Use only if clearly needed. Limited breast milk data.
Storage
Store at 25C (77F); excursions permitted 15-30C (59-86F). Dispense in tight, light-resistant container.
Frequently Asked Questions
What is Famotidine used for?▼
Treatment of active duodenal ulcer, active gastric ulcer, symptomatic nonerosive GERD, and erosive esophagitis due to GERD in adult and pediatric patients 40 kg and greater. Also for pathological hypersecretory conditions and duodenal ulcer recurrence reduction in adults.
What are the side effects of Famotidine?▼
Most common: headache, dizziness, constipation, and diarrhea. Less common: CNS effects, cardiovascular, GI, hematologic, and hypersensitivity reactions. Postmarketing: arrhythmia, jaundice, agranulocytosis, anaphylaxis, Stevens-Johnson syndrome.
Can I take Famotidine during pregnancy?▼
Limited human data; animal studies showed no adverse development effects at doses up to 243 times the recommended human dose. Use only if clearly needed. Limited breast milk data.
What are the important warnings for Famotidine?▼
CNS adverse reactions in elderly and renally impaired patients; reduce dosage accordingly. Absence of GI symptoms does not exclude gastric malignancy; evaluate prior to initiating therapy. Contraindicated with history of serious hypersensitivity reactions to famotidine or other H2 receptor antagonists.
Related Medications
Curcuma Longa,hydrolyzed Collagen,kojic Acid,adenosine
curcuma longa,hydrolyzed collagen,kojic acid,adenosine
Adenosine Receptor Agonist [EPC]
Deeply replenishes moisture, restores elasticity, and enhances skin firmness.
Carya Glabra, Carya Ovata, Carya Laciniosa And Carya Alba
carya glabra, carya ovata, carya laciniosa and carya alba
Dosage form: SOLUTION. Route: INTRADERMAL, PERCUTANEOUS, SUBCUTANEOUS. Active ingredients: CARYA ALBA POLLEN (.025 g/mL); CARYA GLABRA POLLEN (.025 g/mL); CARYA LACINIOSA POLLEN (.025 g/mL); CARYA OVATA POLLEN (.025 g/mL). Category: BLA.
Tebentafusp
tebentafusp
Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC]
11 DESCRIPTION Tebentafusp-tebn is a bispecific gp100 peptide-HLA-directed T cell receptor CD3 T cell engager. Tebentafusp-tebn has an approximate molecular weight of 77 kDa. Tebentafusp-tebn is produced by recombinant DNA technology in Escherichia coli cells. KIMMTRAK (tebentafusp-tebn) injection is supplied in a single-dose vial as a sterile, preservative-free, clear, colorless or slightly yellowish solution for intravenous administration by infusion.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.